Investor presentation - change of venue

OptiBiotix Health Plc

(the "Company" or the "Group")

Investor Presentation - Change of venue

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces a change of venue for the presentation for investors due to take place on Tuesday, 16 February 2016.

Due to popular demand, the event will now be held in the Oriental room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm for a 4.45pm start.

All other details remain the same as stated in the RNS published on 20 January 2016.

To register for the event, please email optibiotix@walbrookpr.com or call the Walbrook PR team below. If you have already registered, you need not take any further action.

About OptiBiotix Health PLC - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.